ArticleDiscover oncology2026
Risk of metastasis and survival in patients with T1-2 non-ampullary duodenal neuroendocrine tumors undergoing different treatment strategies.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundOptimal management of T1-2 non-ampullary duodenal neuroendocrine tumors (NAD-NETs) remains controversial, particularly for intermediate-sized tumors (11-20 mm), due to limited evidence. This study aimed to quantify real-world metastasis risk and compare long-term survival after endoscopic therapy (ET) or surgical therapy (ST) for T1-2N0M0 NAD-NETs.
methodsPatients were identified from the Surveillance, Epidemiology, and End Results (SEER) database and divided into two cohorts: Cohort A (n = 2101), including T1-2 NAD-NETs for metastasis risk-factor analysis; and Cohort B (n = 1496), including T1-2N0M0 NAD-NETs treated with ET or ST for survival comparison. Multivariable logistic regression was performed to assess factors associated with metastasis risk in Cohort (A) Propensity score matching was performed to balance covariates in Cohort (B) Cancer-specific survival (CSS) and overall survival (OS) were calculated and compared between the ET and ST groups.
resultsOverall metastasis incidence at diagnosis was 9.42% (198/2101). Independent metastasis predictors included tumor size 11-20 mm (OR = 4.30, 95% CI:3.00-6.16) and > 20 mm (OR = 14.65, 95% CI:9.38-22.94), and muscularis propria (MP) invasion (OR = 4.94, 95% CI:2.41-10.74). Of the 1496 patients with T1-2N0M0 NAD-NETs, the long-term prognosis was comparable between ET and ST (after matching, 5-year CSS: 99.0% vs. 97.1%, P = 0.031; 5-year OS: 84.6% vs. 87.4%, P = 0.37). Subgroup analyses confirmed equivalent survival for ET versus ST across those measuring 11-20 mm (CSS 97.4% vs. 98.1%, P = 0.694) and those measuring > 20 mm (CSS 100% both).
conclusionET provides comparable long-term survival versus surgery for T1-2N0M0 NAD-NETs and ET could be a viable strategy for well- to moderately differentiated NAD-NETs of 11-20 mm without MP invasion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.